Samsung Biologics has officially taken over the former GSK manufacturing campus in Rockville, cutting the ribbon on its first U.S. production base and keeping more than 500 local jobs in place. The acquisition boosts the South Korean contract manufacturer's biologics footprint on the East Coast, with company and state officials marking the closing at a March 31 ceremony.
Deal details and capacity
The Rockville campus includes two cGMP manufacturing plants with a combined 60,000 liters of drug-substance capacity, according to a Samsung Biologics release. That pushes the company’s global output to roughly 845,000 liters.
Samsung Biologics said it will keep producing existing products for GSK while gradually transitioning the site into a broader contract-manufacturing hub. The company also outlined plans for additional investment to expand capacity and upgrade technology across the campus.
Price and accounting
Samsung initially pegged the deal for the Rockville assets at $280 million, but later figures put the total transaction value closer to $353.1 million once inventories and raw materials are folded in. AJU Press reported that the package breaks down to roughly $280 million for the facility itself and about $73.1 million for inventories, while GSK notes the asset transfer in its own filings.
Jobs and local reaction
State and county leaders quickly framed the move as a big win for Maryland’s life-sciences corridor and for workers who might otherwise have faced an uncertain future.
“We are thrilled that Samsung Biologics has selected Maryland for their first U.S. manufacturing facility,” Gov. Wes Moore said in a statement from the governor’s office. Montgomery County Executive Marc Elrich said the investment protects more than 500 jobs and reinforces the county’s standing as a global life-sciences hub.
Why this matters for the local cluster
The Rockville facility sits in the heart of the I‑270 life-sciences corridor, near federal labs, research universities and major hospitals. Local economic-development officials say that geography could make it easier for Samsung Biologics to recruit specialized talent and plug into an existing network of suppliers.
Rockville Economic Development, Inc. highlighted that the company plans to retain more than 500 employees at the campus and suggested Samsung’s arrival could generate new business for area vendors, noting the company’s announcement on its site. The expansion of U.S.-based manufacturing capacity also tracks with what customers and regulators have been asking for as they focus more on supply-chain resilience.
What to watch next
Samsung Biologics has signaled it will fold Rockville into a two-hub manufacturing model that connects Songdo, Korea, with the new U.S. site and ramp up contract-manufacturing work across North America. In its press materials, the company outlined plans to modernize and expand production capabilities at the campus, a process that could lead to phased hiring, permitting activity and additional supplier contracts in Montgomery County.
Regulators and clients are expected to keep a close eye on how Samsung manages the transition of quality systems and product-release responsibilities as the handover unfolds.
For Rockville and the wider Maryland life-sciences ecosystem, the deal offers continuity for existing workers and the prospect of a steady pipeline of supplier work as Samsung brings the operation fully online. Local officials say they anticipate new job postings, permit filings and vendor agreements to surface as upgrades move ahead.
